Eli Lilly to Cut Pharma Jobs at Singapore R&D Centre

As reported by Fierce Pharma, the global pharmaceutical company Eli Lilly is planning to close its Singapore based Centre for Drug Discovery which could lead to 130 pharmaceutical jobs to be axed.

The move comes as the pharma company attempt to make worldwide cost savings. The plan is to select the best research programmes and shift them to their headquarters in Indianapolis.

Lilly will continue to operate a Phase I clinical which is known as the Lilly NUS (National University of Singapore). In addition, it’s marketing and sales affiliate will stay put, as well as various scientific collaborations with universities and research institutions.

Are you looking for a new role in the pharmaceutical industry? Click here to search our current pharma jobs online now.

Posted in: company news, News
CK Logo in place of featured image